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Background: Suboptimal vitamin D status is highly prevalent in Northern communities, particularly in those
patients with chronic diseases such as diabetes and chronic renal disease. Emerging literature suggests that
adherence to daily vitamin D supplementation may be an important factor influencing vitamin D status and
overall bone health, but compliance with therapies for bone health is a major challenge. It is unknown what
level of vitamin D supplementation will ameliorate or improve suboptimal vitamin D status in patients with
diabetic nephropathy or contribute to improved bone health, particularly for those living in northern climates.
Methods/Design: The study purpose was to examine two different strategies of vitamin D3 supplementation;
daily dosing of 2000 IU per day verses monthly dosing of 40,000 IU per month on markers of vitamin D status,
bone health and to examine whether adherence, quality of life and patient satisfaction with the supplementation
strategy differs between the two vitamin D strategies in adults diagnosed with diabetic nephropathy.
Discussion: The need for RCTs assessing higher doses of vitamin D3 supplementation at varying frequencies of
administration and its impact on bone health in adults with diabetes and chronic kidney disease are needed.
Trial registration: ClinicalTrials.gov NCT01476501.
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Suboptimal vitamin D status (25(OH)D <75 nmol/L) is
associated with the development and progression of
both diabetes and chronic kidney disease (CKD) [1].
Within the general North American population 16-52%
have suboptimal vitamin D status; the prevalence of vita-
min D insufficiency increases to 86% in the diabetic
population and those with concurrent kidney disease are
1.78-fold more likely to be vitamin D deficient [2-4].
Patients living in northern communities are at particu-
lar risk for vitamin D insufficiency due to limited sun-
light exposure, further increasing their risk for low
bone mineral density (BMD) and fragility fractures
[3,5-10]. Recent evidence indicates that up to 40-90%
of patients with stage 3–4 CKD have insufficient/* Correspondence: mager@ualberta.ca
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unless otherwise stated.deficient vitamin D status [2,5,11,12]. By the time CKD
patients reach dialysis, approximately 75% have meta-
bolic bone disease [13].
Unlike other nutrients, recommendations for vitamin
D are not based on food sources as there are very few
dietary options available (e.g. fish, liver and fortified
dairy products), but rather are designed to compensate
for a deficiency of sunlight [14]. This places the indivi-
dual living in northern climates at particular risk for
inadequate vitamin D status, especially in the winter
months when sunlight exposure is unlikely to contribute
to overall vitamin D status. Most evidence suggests that
when vitamin D requirements are met, it is with a com-
bination of dietary vitamin D and a supplement [15-22].
Patients with diabetic nephropathy are at increased risk
for poor dietary intake of vitamin D due to restrictions
on vitamin D rich foods/beverages (e.g. dairy based pro-
ducts) as these products also have a high carbohydrate,
phosphorus and/or potassium content. It is unknown whatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prove suboptimal vitamin D status in patients with diabetic
nephropathy or contribute to improved bone health,
particularly for those living in northern climates [5,7,10]. A
recent study in patients with stage 3–4 CKD demonstrated
that daily oral supplementation of vitamin D3 (1,000 IU/d)
for three months resulted in a mean increase in serum
25(OH)D of 25 nmol/L (40 ± 15 nmol/L pre- vs. 68 ±
25 nmol/L post-supplementation); a significantly lower
level of 25(OH)D than is thought to optimize bone
health (>100 nmol/L) [12,23-25].
Emerging literature suggests that adherence to daily
vitamin D supplementation may be an important factor
influencing vitamin D status, and compliance with ther-
apies for bone health (like other asymptomatic condi-
tions) is a major challenge [26-28]. Chronic diseases,
such as poor bone health, as well as suboptimal vitamin
D status, have been associated with reduced quality of
life (QoL) [26,29-31]. Despite the potential for improved
functional ability and independence, only 50-69% of
individuals prescribed osteoporosis medications (e.g.
bisphosphonates, vitamin D and calcium) comply to
them regularly (e.g. consume 80% of the time), and only
25-35% are compliant for more than one year [29-31].
This suggests that current modes of vitamin D supple-
mentation in adults with diabetic nephropathy, particu-
larly low dose daily administration (<1,000 IU/d), may
be ineffective at optimizing vitamin D status. Higher
daily doses (>1,000 IU/d) or the use of high dose, less
frequent modes of administration (monthly vs. daily),
need to be explored to ensure improved compliance to
dosing strategies and adequacy of overall vitamin D sta-
tus, particularly in those populations at high risk for
vitamin D insufficiency and suboptimal bone health (e.g.
diabetic nephropathy).
Purpose
The first study aim was to investigate the impact of daily
vs. monthly vitamin D3 supplementation on vitamin D
status and markers of bone health in adults with diabetic
nephropathy. The second study aim was to compare
participant adherence and satisfaction between two dif-
ferent vitamin D3 supplementation strategies (daily vs.
monthly), and quality of life (QoL).
Objectives
1. Examine the impact of two approaches to high dose,
oral, vitamin D3 supplementation (2,000 IU/d vs.
40,000 IU/m) for 6 months on overall vitamin D
status (25(OH)D and 1,25(OH)2D) and markers of
bone turnover (bone-specific alkaline phosphatase,
osteocalcin, N-telopeptide of type 1 collagen) in
adult patients with diabetic nephropathy.2. Examine daily vs. monthly vitamin D3
supplementation strategies in regards to adherence,
patient satisfaction and quality of life in adult
patients with diabetic nephropathy.Hypotheses
1. Vitamin D3 supplementation (2,000 IU/d vs.
40,000 IU/m) for 6 months will result in significantly
improved overall vitamin D status and improved
markers of bone health in adult patients with
diabetic nephropathy. Serum 25(OH)D will
increase by a minimum of 25–50 nmol/L post-
supplementation. Markers of bone resorption will
decrease and markers of bone formation will increase
after 6 months of vitamin D3 supplementation when
compared to baseline levels.
2. Monthly dosing of vitamin D3 (40,000 IU/m) over
6 months will result in improved patient adherence
and satisfaction with vitamin D3 supplementation
when compared to daily dosing of vitamin D3
(2,000 IU/d) resulting in improved overall vitamin D
status, bone health parameters, and quality of life.Methods
Study design
The study design was a randomized, controlled, open-
label trial comparing the effectiveness of two vitamin D3
dosing strategies (monthly vs. daily) on vitamin D status
and markers of bone health in adults with diabetes and
nephropathy over a 6 month period. Patients were ran-
domized to one of the two vitamin D3 supplementation
strategies in blocks of 30 using a random number gener-
ator (http://www.randomizer.org) by one graduate stu-
dent (SJ): once monthly (40,000 IU/m; n = 60) or once
daily (2,000 IU/d; n = 60) for six months. All members of
the research team (with the exception the graduate stu-
dents (SJ/MH)) were blinded to study allocation. Both
vitamin D supplements contain vitamin D3 (cholecalciferol)
in gel capsule form; Jamieson Natural Sources® Vitamin D
1,000 IU Soft gel (NPN 80017530), and EURO-Pharm
International Canada Inc.® EURO D 10,000 IU (DIN
02253178). The two dosing regimens were: 2 capsules
of 1,000 IU vitamin D daily (total dose = 2,000 IU/d),
or 4 capsules of 10,000 IU vitamin D at the end of each
month (total dose = 40,000 IU/m). The daily dose was
selected based on results from findings that showed
that patients with diabetes with stage 3–4 CKD in Northern
Alberta where supplementation with 1000 IU/D vitamin
D3 resulted in serum increases of 25(OH) vitamin D less
than 25 mmol/L [5,7]. A monthly dose of 40,000 IU/m vita-
min D3 was chosen to achieve equivalent supplementation
to daily dosing assuming an adherence rate of 69%, and
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of 100 nmol/L [27,32].
This study was approved by the Human Research
Ethics Board at the University of Alberta (File Number:
Pro00022639), has received a “No Objection Letter” from
Health Canada (Control File Number 148625), and is a
registered clinical trial (NCT01476501). The study was
monitored by a Drug and Safety Monitoring Board (DSMB)
with annual safety reports submitted as per Health Canada
protocol. Reporting of study results will be according to the
CONSORT (Consolidated Standards of Reporting Trials)
Guidelines [33].
Participants
Patients were recruited from Northern Alberta Renal
Program (NARP) clinics at Alberta Health Services
(AHS) in Edmonton, Alberta between November 2011
and December 2013. This is a multidisciplinary program
(endocrinologists, nephrologists, registered nurses (RN),
registered dietitians (RD), pharmacists and social workers)
that provides care to over 1,500 patients with diabetic ne-
phropathy in northern Alberta. Sixty adults with diabetes
and nephropathy per vitamin D3 supplementation group
were recruited into this study (n = 120 total). Potential par-
ticipants were approached by a member of the clinical team
(e.g. RD or RN) and asked if a research team member could
discuss this study with them. If verbal consent was pro-
vided, then a research team member contacted the patient,
explained the study to them and determined their eligibility
for participation in this RCT; if eligible and agreed by the
patient, informed consent was signed and the baseline
study appointment was booked. Subsequent study visits
(e.g. 3 month and 6 month follow-up appointments) were
booked via telephone calls made approximately 2 months
later to follow-up with the participants and address any
questions or concerns they may have had about their
supplement strategy. Patient eligibility for this RCT
was determined upon information available in the
medical chart at time of screening. Inclusion/exclusion
criteria are as follows:
Inclusion criteria
1) Adult (18–80 years) patients diagnosed with
diabetes (Type 1 and Type 2) and stage 1–4 CKD
(Glomerular Filtration Rate (GFR) 15–89 mL/min/
1.73 m2) [34].
Exclusion criteria
1) Patients with co-morbid conditions known to affect
vitamin D metabolism including gastrointestinal,
liver, rheumatoid or bone disorders (e.g.
hyperthyroidism, untreated celiac disease, cancer,Paget’s disease, sarcoidosis, malabsorption, etc.).
Individuals with severe, permanent vision impairment
will be excluded as this will preclude them from
reading supplement labels accurately and safely.
Pregnant women will be excluded as Dual-energy
X-ray Absorptiometry (DXA) scans are not
recommended during pregnancy. Patients weighing
>136 kg will be excluded as the DXA table cannot
accommodate this weight.
2) Patients on drug therapy known to interfere with
vitamin D (e.g. oral glucocorticoids, cholestyramine,
colestipol, mineral oil, Orlistat, digoxin).
3) Patients on other forms of active D metabolites
(e.g. calcitriol, vitamin D2).
4) Patients with stage 5 CKD (GFR <15 mL/min/1.73 m2),
receiving dialysis or on a kidney transplant list.
5) Patients with pre-existing hypercalcemia
(>2.75 mmol/L), hyperphosphatemia (>2.0 mmol/L),
severe secondary hyperparathyroidism (PTH >66
pmol/L), and serum 25(OH)D >200 nmol/L.
6) Patients with serum 25(OH)D <37.5 nmol/L at time
of screening to control for correction of vitamin D
deficiency [5].
7) Patients undergoing strict heavy exercise for weight
control and/or those who used sunscreen lotion on
a regular basis.
Sample size
This sample size (n = 120) was based on the ability to
detect a mean difference of 25–50 nmol/L in serum 25
(OH)D from baseline levels after 6 months of vitamin
D3 supplementation in each group (α = 0.05 and β = 0.8)
with an additional 15% to account for potential subject
attrition [5,8]. Recent evidence has shown that a mean
increase of 25 nmol/L in 25(OH)D with 1,000 IU/day
supplemental vitamin D3 was insufficient to promote 25
(OH)D in excess of 100 nmol/L – the level of 25(OH)D
that has been associated with having a beneficial impact
on markers of bone health [5,7,23]. Therefore, we chose
this specific vitamin D3 dose to ensure serum 25(OH)D
would increase by 25–50 nmol/L.
Data collection
Assessment of vitamin D status, bone health and lifestyle
factors (diet, physical activity, sunlight exposure, QoL)
were performed during study visits at the Clinical Research
Unit (CRU) at the University of Alberta at baseline, 3 and
6 months post study enrolment between January 2012 and
June 2014. Participants were given a 3 month supply of
their respective vitamin D3 supplementation strategy at
baseline and again at the 3 month study visit. They were
asked to return their vitamin D3 vials/pill containers to the
study investigators at the 3 and 6 month study visits. At
baseline, information related to patient demographics and
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ethnicity, medications/supplement use, insulin regimen,
height, weight (Health O-Meter Professional model 597KL,
Pelstar LLC, Alsip, IL, USA) and BMI. Changes in these
variables between appointments were documented (e.g.
medications, height, weight). Bone mineral density (BMD)
was measured at baseline using Dual-energy X-ray Absorp-
tiometry (DXA); a validated tool to assess BMD (General
Electric LUNAR Prodigy, version 10.5, Madison, WI, USA).
Whole body scans as well as site specific scans of the lum-
bar spine (L1-L4) and left total hip (including femoral neck)
were conducted. The precision error, expressed as a per-
centage coefficient of variation (%CV), for the Lunar DXA
located in the CRU are as follows: whole body BMD 0.7%,
lumbar spine 0.9% and total hip 1.2%.
Lifestyle factors were assessed at baseline, 3 and
6 months using validated tools [35-41]. These include:
1) 3-day food record to assess vitamin D and calcium intake
and other dietary factors known to influence vitamin D and
bone health (phosphorus, carbohydrates, protein, caffeine).
Dietary intake was analyzed using the Food Processor Data-
base (Food Processor SQL, v.10.8, ESHA Research, Salem,
Oregon, USA); 2) Weight-bearing physical activity records;
3) Sunlight exposure questionnaires; 4) Health related QoL
(SF-36) questionnaires (www.qualitymetric.com Liscence
Number QM019185 OPTUMInsightTDM); and 5) Adher-
ence and acceptance surveys [34-38,42-44]. Adherence to
vitamin D3 supplementation was also assessed by pill
counts of returned vitamin bottles at 3 and 6 months.
Laboratory investigations
To avoid risk of hypoglycemic events due to variations
in appointment availability (e.g. insulin regimen incom-
patibility with fasting and later appointment times), ran-
dom serum/plasma samples for measurement of routine
clinical blood work and study blood work were collected.
However, most blood samples were collected between
10 am-2 pm; approximately 2 hours post meal consump-
tion (of either breakfast or lunch) to minimize the
potential influences of variable blood collection times on
bone turnover marker expression [39].
Blood samples were collected onsite at each research
visit by a trained phlebotomist using validated tech-
niques and tubes (SST gel for serum, and lithium hep-
arin PST gel and EDTA plasma). Once collected, blood
samples were immediately held at 2-8°C until processing
by the research team or provincial laboratory system.
Patients routinely receive clinical blood work to assess
their glycemic control, kidney function and overall
health, including: estimated GFR (eGFR), fasting/random
blood glucose (FBG/RBG), urea, creatinine, hemoglobin
A1c (HbA1c), calcium, albumin, phosphorus, magnesium,
25(OH)D and PTH. These variables were collected at all 3
study visits (except PTH) along with 1,25(OH)2D status.Serum PTH, bone turnover markers and fibroblast growth
factor-23 (FGF-23) were collected at baseline and 6 month
follow-up study visits.
Routine clinical blood work, 1,25(OH)2D and PTH
were measured by validated, specific and sensitive method-
ologies used by the provincial laboratory system. Estimated
GFR was calculated using a validated online equation pro-
vided by K/DOQI (Modification of Diet in Renal Disease
(MDRD) study group and the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) group; http://
www.kidney.org/professionals/kdoqi/gfr_calculator.cfm).
Bone turnover markers were analyzed by the research
team using standardized commercial ELISA kits. After
blood collection, EDTA plasma and serum clot samples
(e.g. SST gel) were kept for approximately 30–60 mi-
nutes at 2-8°C and then centrifuged at 2,500 RPM at 4°C
for 10 minutes (CR4.22 centrifuge, Jouan, Winchester,
VA, USA). Recovered serum and plasma were aliquoted
into clean micro-tubes according to volumes required
for each specific assay to be tested in duplicate. Samples
were stored frozen at −80°C until ELISA testing, and
prepared according to the manufacturer instructions for
each commercial ELISA kit: serum intact osteocalcin
(OC; MicroVue Osteocalcin EIA Kit, Quidel, San Diego,
CA, USA), serum bone-specific alkaline phosphatase
(BAP; MicroVue BAP EIA Kit, Quidel, San Diego, CA,
USA), serum N-telopeptide of type 1 collagen (NTx;
Osteomark NTx Serum, Wampole Laboratories, Prince-
ton, NJ, USA), and plasma intact fibroblast growth
factor-23 (FGF-23; Human Intact FGF-23 ELISA Kit,
Immunotopics Inc, San Clemente, CA, USA). The intra-
assay (a) and inter-assay (b) coefficient of variance (CV)
for these commercial kits are as follows: OC a) 4.8-
10.0%, b) 4.8-9.8%; BAP a) 3.9-5.8%, b) 5.0-7.6%; NTx
a) 4.6-13.99%, b) 6.9-13.99%; and FGF-23 a) 2.6-4.4%,
b) 6.1-6.5%.
Outcome measurements
Outcome measurements are illustrated in Figure 1.
Primary outcome variables
Serum 25(OH)D and 1,25(OH)2D
Serum 25(OH)D is considered the most reliable measure
of vitamin D status as it accounts for cutaneous and
dietary sources of vitamin D [40].
A mean increase in serum 25(OH)D of 25–50 nmol/L
was chosen as a conservative target for 25(OH)D as
1,000 IU/d has been shown to increase serum 25(OH)D
by 25 nmol/L in renal patients [5]. 1,25(OH)2D was
measured to determine concentration of active vitamin
D in participants and explore the relationship of active
vitamin D with 25(OH)D levels and with bone health.
Vitamin D levels were measured by validated, specific
and sensitive methodologies used by the provincial
Baseline:
Randomize to either 2,000IU/d (n=60) or 40,000IU/m (n=60) for 
6 months, and provide 3 month supply.
Anthropometric and Demographics: postal code, age, gender, 
diabetes duration, comorbidities, medications and supplement use, 
height, weight, BMI.
DXA: Absolute BMD and T-score at the spine (L1-L4), left total 
hip, and left femoral neck.
Questionnaires: 3 day food and activity record, sunlight exposure 
and quality of life (SF-36).
Blood collection: HbA1c, BG, eGFR, creatinine, urea, albumin, 
ALP, calcium, magnesium, phosphorus, 25(OH)D (routine clinical 
blood work); PTH, 1,25(OH)2D, OC, BAP, NTx, FGF-23.
6 month Follow-up:
Anthropometric and Demographics: medications and 
supplement use, height, weight, BMI.
Questionnaires: 3 day food and activity record, sunlight 
exposure, quality of life (SF-36), adherence and acceptance 
survey.
Blood collection: routine clinical blood work; PTH, 
1,25(OH)2D, OC, BAP, NTx, FGF-23.
Pill count
Eligible adults with diabetes and chronic kidney disease recruited from 
NARP clinics (AHS) and enrolled in RCT (n=120).
3 month Follow-up:
Anthropometric and Demographics: medications and 
supplement use, height, weight, BMI.
Questionnaires: 3 day food and activity record, sunlight 
exposure, adherence and acceptance survey.
Blood collection: routine clinical blood work and 1,25(OH)2D
Pill count; provide final 3 month supply of vitamin D.
Figure 1 Study design1. 1Abbreviations: Northern Alberta Renal Program (NARP); Alberta Health Services (AHS); randomized controlled trial
(RCT); micrograms (mcg); Body mass index (BMI); Dual X-ray absorptiometry (DXA); Bone mineral density (BMD); Hemoglobin A1c (HbA1c);
random blood glucose (RBG); estimated glomerular filtration rate (eGFR); 25-hydroxy vitamin D (25(OH)D); 1,25-dihydroxy vitamin D (1,25
(OH)2D); alkaline phosphatase (ALP); osteocalcin (OC); bone-specific alkaline phosphatase (BAP); N-telopeptide of type 1 collagen (NTx);
fibroblast growth factor-23 (FGF-23).
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25(OH)D (precursor) was calculated as a surrogate
measure of 1α-hydroxylase activity (product to precursor
ratio).
Bone health
Bone health was assessed by measurement of BMD and
plasma/serum levels of bone turnover markers. BMD
was measured using DXA (non-invasive gold standard)
to characterize bone health of participants at time of study
entry. Bone turnover markers were measured at baseline
and at 6 months; bone resorption: N-telopeptide type 1 col-
lagen (NTx); and bone formation: bone-specific alkaline
phosphatase (BAP) and osteocalcin (OC) [34]. Serum PTH
and fibroblast growth factor-23 (FGF-23; measure of
bone-kidney axis) were measured at baseline and 6 months
to assess how serum PTH/FGF-23 concentrations change
with our vitamin D supplementation strategies.Secondary outcome variables
Participant acceptance and adherence survey
Participants completed a validated survey developed to
assess adherence to drug therapy in adults with chronic
disease (e.g. hypertension) that has been adapted for our
specific therapy [37]. This survey consists of open and
close-ended questions. This was used to assess and com-
pare adherence to the two different dosing strategies,
and consider participants’ preferences and perceptions
of their supplementation strategy. Adherence to the
dosing regimens was also assessed by pill counts (at 3
and 6 month visits).
Health-related QoL questionnaire (SF-36)
Participants completed the SF-36 QoL questionnaire
(a common and validated tool used to asses QoL in
chronic disease) at baseline and 6 months after study
entry [38]. This questionnaire considers parameters of
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tional well-being and was used to compare QoL pre-
and-post intervention. (Liscence Number QM019185
OPTUMInsight TDM).
Dietary intake
3-day food records (2 weekdays, 1 weekend day), a
validated tool for diet analysis, were completed [36,44].
Responses were verified by an RD on the research team
(blinded to study allocation) and analyzed for micro-
and macronutrient intake (e.g. calcium, vitamin D, phos-
phorus, carbohydrates, protein and caffeine) using Food
Processor® (Canadian Nutrient File®).
Weight-bearing physical activity
Analysis of the frequency/duration/effects of weight-
bearing physical activity utilizing a record adapted from
a validated physical activity questionnaire [34,42].
Sunlight exposure questionnaire/seasonal affects
Participants completed a validated questionnaire for
vitamin D synthesis potential according to sun expos-
ure behaviours [43]. This questionnaire was completed
to help account for seasonal variations and the impact
this may have on vitamin D synthesis.
Safety variables and analysis
Safety analysis included an evaluation of the literature
and the potential for the following: 1) hypercalcemia
[27,41,45] 2) signs and symptoms of acute toxicity (rare)
including evidence “anorexia, nausea, vomiting, fatigue,
confusion, headache, weakness, renal impairment, ar-
rhythmias, hypertension, calcification of soft tissue and
hyperphosphatemia” [41].
Adverse events with vitamin D3 supplementation at
these dosing levels (40,000 IU/month or 2000 IU/D)
have not been routinely reported in the literature
[11,45-47]. Supplementation with active vitamin D ana-
logues may be useful for individuals with severely dimin-
ished renal function and capacity for active hydroxylation,
and is primarily used to treat severe hyperparathyroidism.
However, providing already active vitamin D results in
bypassing the homeostatic controls that are in place to pre-
vent vitamin D toxicity (e.g. reducing 25-hydroxylation and
increasing catabolism and excretion of 25(OH)D via bile),
which in turn can increase risk for vitamin D toxicity
[23,46]. Serum phosphate (>2.0 mmol/L), calcium-
phosphorous product (CaP; >4.4 mmol2/L2) and magne-
sium (>1.0 mmol/L) are all monitored as part of routine
clinical care for variation from healthy ranges [41].
A data safety monitoring board (DSMB) was included
within the study design. All adverse events (AE) were
documented. AEs were identified as related to the study
protocol (e.g. anything directly related to our vitamin Dsupplementation intervention, blood collection or other
examinations in the study protocol) or not related to the
study protocol. Serious adverse events (SAEs) were de-
fined as significant health/safety issues (e.g. acute renal
failure, death). The responsible physician (PS), University
HREB, and DSMB were notified of all AE/SAE. No SAEs
due to study protocol occurred in this study.
Concomitant medication
Patients were asked to continue taking their normal
medications as advised by their physician, e.g. insulin,
oral hypoglycaemic agents, anti-hypertensives, statins,
diuretics, phosphate binders, potassium lowering agents,
anemia treatment, Replavite, and/or proton-pump inhibi-
tors. Concomitant medications were reviewed at each visit
to ensure excluded medications were not prescribed in the
interim. Any patients medically requiring a concomitant
medication that was contraindicated were released from
the study. Participants were asked to discontinue all
vitamin/mineral supplements containing calcium and/or
vitamin D unless prescribed for therapeutic treatment (such
as calcium carbonate-containing antacids for treatment of
hyperphosphatemia). Those on active vitamin D treatment
(with other vitamin D metabolites) were excluded from
the study.
Rescue medication & risk management
Serum phosphate (>2.0 mmol/L), CaP product (>4.4 mmol2/
L2) and magnesium (>1.0 mmol/L) were monitored
throughout the study [48]. Vitamin D toxicity was ad-
dressed in the following ways: a) discontinuation of vitamin
D3 supplement and b) notification to the Qualified Investi-
gator (PS) and other members of the health care team in
NARP/DNPC.
The following were standard responses to vitamin D
toxicity in our population: 1) Serum and urine electro-
lytes, renal function, electrocardiogram, and fluid bal-
ance monitoring and maintenance [38]. 2) If necessary,
additional measures may have been taken to enhance ex-
cretion/metabolism of the vitamin D including: IV adminis-
tration of furosemide; corticosteroid, bisphosphonate or
calcitonin therapy; hemo- or peritoneal dialysis [43]. If
hypersensitivity to vitamin D3 occurred which included
anaphylaxis, then appropriate treatment with epinephrine
and ventilation would have been provided as needed.
Adverse events were reported immediately to the re-
sponsible physician (PS) or the on-call endocrinologist/
nephrologist was notified as per standard clinical care.
Participants were taken to the University of Alberta
Hospital, AHS if requiring immediate medical treatment.
Premature withdrawal
Participants were able to voluntarily withdraw from the
trial at any time without any negative consequences to
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drop out were documented. Any individual demonstrat-
ing clinical signs and symptoms of vitamin D toxicity
and/or an SAE related to the study protocol resulted in:
1) vitamin D3 supplementation discontinued, 2) respon-
sible physician (PS) notified so the patient received treat-
ment for toxicity (as above), 3) notification of the DSMB
and Health Canada, and 4) patient participation in the
study was discontinued. New medical diagnosis arising
precluding the ability to continue in the study was an
additional reason for premature withdrawal. This was
assessed by the qualified investigator (PS).
Statistical analysis
Data analysis was performed on an intention-to treat
basis as well as a per-protocol basis. Analyses were per-
formed using Microsoft Excel 2010 and Statistical Ana-
lysis Software (SAS; version 9.3 SAS Institute, Cary, NC,
USA). Statistical significance was determined at p < 0.05.
Continuous variables were expressed as mean, median,
ranges, and standard error (SE) or standard deviation
(SD). The differences between dosing type (daily vs.
monthly) over the intervention period were assessed by
repeated measures analysis of variance, followed by a
post-hoc pair-wise t-test with Bonferroni corrections to
assess for within and between group comparisons. Po-
tential risk factors for the development of vitamin D
insufficiency (serum 25(OH)D <75 nmol/L) and poor
bone health (T-scores < −2 SD) in adults with diabetic
nephropathy include bone turnover, vitamin D intake,
vitamin D status (serum levels of 25(OH)D and 1,25
(OH)2D), age, gender, ethnicity, severity of kidney dis-
ease, diabetic management/control, exposure to sunlight,
level of activity, and psychosocial and lifestyle factors.
Continuous and categorical variables (e.g. 25(OH)D,
lab parameters, BMD T-scores, adherence scores) were
quantitatively analyzed, and open-ended questions re-
garding participants’ perceived facilitators and barriers
were categorized into key themes. Bivariate and univari-
ate analysis were done to assess the potential effect of
these variables on vitamin D status and bone health
(bone turnover markers).Variables shown to be associ-
ated with a poor vitamin D status were assessed using
multivariate logistic regression models to determine risk
for development of vitamin D deficiency and poor bone
health. Regression analysis was also conducted to assess
correlation between biochemical parameters (PTH, 25
(OH)D, 1,25(OH)2D, calcium, phosphorus, magnesium,
albumin, eGFR, RBG) and bone turnover markers. Ana-
lysis of variance was performed to assess for significant
differences in vitamin D status and bone turnover
markers over the intervention period in both groups. Re-
gression analysis was performed with serum 25(OH)D
and plasma PTH as categorical variables; e.g. 25(OH)Dsorted by greater/less than 75 nmol/L and plasma PTH
sorted by greater/less than 7.15 pmol/L, the optimal
concentrations for bone health [5,26]. Where necessary,
vitamin D was adjusted for potential confounding vari-
ables (e.g. age, gender, ethnicity, disease severity) using
an analysis of co-variance. When adherence to daily vita-
min D dosing regimen was greater or less than 69%, the
variation in compliance was also accounted for in an ana-
lysis of co-variance. For variables demonstrating skewed
distributions a logarithmic transformation was used to
normalize the data.
Data management and validation
Prior to data entry, these individuals underwent ethics
training and evaluation related to protecting participant
information and health, including online University of
Alberta and National Institute of Health ethics training
and testing, criminal record checks, and ensuring up-to-
date immunizations. Source data was coded and kept in
a locked filing cabinet within the Clinical Research Unit,
University of Alberta. Electronic files were encrypted
and kept in a password protected computer according to
University of Alberta (Faculty of Medicine) encryption
policy [49].
The electronic data was audited in a timely manner to
ensure any discrepancies were addressed and the poten-
tial for future discrepancies was reduced. A variety of
standard operating procedures (SOP) were developed to
support data analysis. Discrepant results were compared
with source records, and amendments were made to
the electronic records as necessary. All data entry was
cross verified by one trained volunteer/graduate stu-
dent, along with the primary graduate students in-
volved in the project.
Discussion
Vitamin D is a nutrient of concern for individuals with
diabetes and nephropathy, particularly for those living in
northern climates with limited sunlight exposure. Dietary
restriction of vitamin D-rich food sources (e.g. dairy prod-
ucts) is a common issue due to concerns around phos-
phorus, potassium and carbohydrate content. Avoidance of
sunlight is also common due to instructions for concomi-
tant medications. Vitamin D supplementation is required in
this population, yet the most effective dose and most effi-
cient dosing strategy is unknown. Low adherence rates to
routine vitamin D supplementation is also an inherent chal-
lenge and therefore developing alternative approaches such
as alterations in dosing frequency (monthly verses daily) is
also an important consideration [26]. Previous studies have
been limited by small sample size, short intervention
duration or retrospective design. This study prospectively
investigated the impact of two different oral vitamin
D3 supplementation dosing strategies (2,000 IU/d vs.
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status and bone health in a large group of adults with
diabetes and nephropathy.
Measurement of markers of dynamic expression of
bone turnover, enables evaluation of changes over time
versus assessment of static changes in bone physiology
that could be observed via DXA [50] is a conferred
added strength. Markers of collagenous bone resorption
(e.g. serum NTx), bone formation (e.g. serum BAP and
OC), and the bone-kidney axis/mineral homeostasis (e.g.
plasma FGF-23) will allow for exploration of dynamic bone
remodeling during vitamin D supplementation. These
markers have also been suggested as valuable tools for
assessing adherence to bone health therapies [51].
Conferred additional strengths to the study design in-
clude the evaluation of socio-demographic, co-morbidities,
concomitant medication use and quality of life factors; all
factors known to influence adherence to vitamin supple-
mentation. Ongoing analysis will enable a comprehensive
evaluation of both lifestyle and physiological factors that in-
fluence response to vitamin D supplementation in this
population. Dietary intake will be analyzed using validated
methodologies for its contribution to total vitamin D intake
and status, as well as intake of other nutrients that are
known to impact bone health (e.g. calcium, magnesium,
phosphorus). Finally, participants were enrolled throughout
two calendar years, thus accounting for seasonal variations
in vitamin D status. They completed sunlight exposure
and weight-bearing physical activity questionnaires at each
appointment so that potential impact of sunlight exposure
during the different seasons as well as indoor and outdoor
activity can be assessed for impact on vitamin D status
and BMD.
Increasing evidence suggests that current recommen-
dations for vitamin D intake are inadequate, particularly
for populations at risk for suboptimal vitamin D status,
such as those with diabetes, kidney disease or living in
northern climates [3,5,7,27]. Moreover, the need for
RCTs assessing higher doses of vitamin D3 supplementa-
tion at varying frequencies of administration and its im-
pact on bone health in this population is supported by
the research community [3,12,27,35,52,53]. The present
study will help fill this gap in the literature, and elucidate
an appropriate vitamin D3 supplementation dose for im-
proved vitamin D status and bone health in adults with
diabetes and nephropathy [12,27,35,52,53].
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